Vaxart Inc (VXRT)
0.9588
-0.06
(-6.00%)
USD |
NASDAQ |
May 17, 16:00
0.9581
0.00 (0.00%)
After-Hours: 20:00
Vaxart Enterprise Value: 132.89M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 132.89M |
| May 16, 2024 | 143.71M |
| May 15, 2024 | 130.38M |
| May 14, 2024 | 116.25M |
| May 13, 2024 | 108.34M |
| May 10, 2024 | 88.01M |
| May 09, 2024 | 92.71M |
| May 08, 2024 | 92.43M |
| May 07, 2024 | 93.91M |
| May 06, 2024 | 98.83M |
| May 03, 2024 | 92.23M |
| May 02, 2024 | 95.79M |
| May 01, 2024 | 87.23M |
| April 30, 2024 | 89.72M |
| April 29, 2024 | 89.47M |
| April 26, 2024 | 88.84M |
| April 25, 2024 | 79.77M |
| April 24, 2024 | 88.84M |
| April 23, 2024 | 95.15M |
| April 22, 2024 | 98.18M |
| April 19, 2024 | 96.95M |
| April 18, 2024 | 112.29M |
| April 17, 2024 | 116.50M |
| April 16, 2024 | 121.50M |
| April 15, 2024 | 124.10M |
| Date | Value |
|---|---|
| April 12, 2024 | 124.28M |
| April 11, 2024 | 146.92M |
| April 10, 2024 | 141.62M |
| April 09, 2024 | 146.92M |
| April 08, 2024 | 153.98M |
| April 05, 2024 | 153.98M |
| April 04, 2024 | 162.81M |
| April 03, 2024 | 180.46M |
| April 02, 2024 | 182.22M |
| April 01, 2024 | 192.82M |
| March 31, 2024 | 192.82M |
| March 28, 2024 | 186.31M |
| March 27, 2024 | 184.57M |
| March 26, 2024 | 172.40M |
| March 25, 2024 | 174.14M |
| March 22, 2024 | 179.35M |
| March 21, 2024 | 174.14M |
| March 20, 2024 | 175.88M |
| March 19, 2024 | 161.97M |
| March 18, 2024 | 161.97M |
| March 15, 2024 | 148.06M |
| March 14, 2024 | 151.53M |
| March 13, 2024 | 156.75M |
| March 12, 2024 | 158.49M |
| March 11, 2024 | 160.23M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-16.37M
Minimum
Dec 27 2022
2.446B
Maximum
Feb 02 2021
309.34M
Average
161.15M
Median
Feb 07 2024
Enterprise Value Benchmarks
| Novavax Inc | 1.604B |
| Allogene Therapeutics Inc | 193.47M |
| Inovio Pharmaceuticals Inc | 205.31M |
| Stereotaxis Inc | 161.38M |
| Capricor Therapeutics Inc | 157.31M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.42M |
| Revenue (Quarterly) | 2.181M |
| Total Expenses (Quarterly) | 26.25M |
| EPS Diluted (Quarterly) | -0.14 |
| Profit Margin (Quarterly) | -1.12K% |
| Earnings Yield | -55.28% |
| Normalized Earnings Yield | -55.28 |